华蟾素片联合肝动脉化疗栓塞术治疗原发性肝细胞癌的临床疗效及其影响因素分析  

Analysis of the efficacy and influence factors for treatment of primary hepatocellular carcinoma by Huachansu tablets combined with transarterial chemoembolization

作　　者：程健珊 张弢[3] 吴珺玮[4] 高惠峰 陈敬贤[5] 孟志强[1,2] CHENG Chienshan;ZHANG Tao;WU Junwei;GAO Huifeng;CHEN Jingxian;MENG Zhiqiang(Department of Integrative Oncology,Shanghai Cancer Center,Fudan University,Shanghai 200032,China;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China;Department of General Surgery,Ruijing Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Department of Oncology,Ruijing Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Department of Traditional Chinese Medicine,Ruijing Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)

机构地区：[1]复旦大学附属肿瘤医院中西医结合科,上海200032 [2]复旦大学上海医学院肿瘤学系,上海200032 [3]上海交通大学医学院附属瑞金医院普外科,上海200025 [4]上海交通大学医学院附属瑞金医院肿瘤科,上海200025 [5]上海交通大学医学院附属瑞金医院中医科,上海200025

出　　处：《外科理论与实践》2024年第4期351-357,共7页Journal of Surgery Concepts & Practice

基　　金：国家临床重点专科(ZDZK1102);国家自然科学基金青年项目(82202839)。

摘　　要：目的:评价华蟾素片联合肝动脉化疗栓塞术(TACE)治疗原发性肝细胞癌(HCC)效果及其影响因素。方法:按照纳入和排除标准收集108例HCC病人的临床资料,随机分为试验组和对照组。试验组采用华蟾素片联合TACE治疗,对照组采用单纯TACE治疗。以无进展生存期(PFS)和总生存期(OS)作为评价指标,采用COX回归分析评价两组生存预后及其影响因素。结果:试验组OS 13.5个月,对照组OS 9.2个月;试验组PFS 6.8个月,对照组PFS 5.3个月,组间比较,差异均有统计学意义(P均<0.05)。多因素COX回归分析显示,Child⁃Pugh分级和肝硬化是HCC病人PFS预后独立的危险因素;Child⁃Pugh分级是HCC病人OS预后独立的危险因素;ALBI是HCC病人OS预后的保护因素。结论:华蟾素片联合TACE治疗HCC有效延缓肝癌进展,延长病人PFS和OS,其中Child⁃Pugh分级、肝硬化和ALBI是影响HCC病人预后的重要因素。Objective To evaluate the efficacy of Huachansu tablets combined with transarterial chemoembolization(TACE)for treatment of primary hepatocellular carcinoma(HCC)and prognostic influence factors.Methods One hundred and eight patients with HCC were recruited according to the inclusion and exclusion criteria.Patients were randomly divided into treatment group and control group.The treatment group was treated with Huachansu tablets combined with TACE,and the control group was treated with TACE alone,with overall survival time(OS)and progression⁃free survival time(PFS)as the evaluation indexes.The COX regression analysis was used to evaluate the survival and prognostic effects and their influence factors in both groups.Results A total of 108 HCC patients were enrolled.The OS was 13.5 months in treatment group and 9.2 months in control group;the PFS was 6.8 months in treatment group and 5.3 months in control group,and the differences were significant statistically(all P<0.05).Multivariate COX regression analysis showed that Child⁃Pugh grade and cirrhosis were the independent risk factors for PFS in HCC patients.Child⁃Pugh grade were the independent risk factors for OS in HCC patients.ALBI is a protective factor for OS in HCC patients.Conclusions The treatment of HCC by Huachansu tablets combined with TACE can delay the progression of HCC and prolong PFS and OS of the patients with HCC.Child⁃Pugh grade,cirrhosis status,and ALBI were important factors affecting the prognosis of the patients with HCC.

关 键 词：肝细胞癌 华蟾素 肝动脉化疗栓塞术 影响因素 

分 类 号：R735.7[医药卫生—肿瘤]